Physician profile
Thomas Powell
NPI 1316968928
$3,417.57
in general payments reported to CMS, 2019-2025
39 companies · $873 in 2025
The $873 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $204 · 2021: $328 · 2022: $315 · 2023: $583 · 2024: $672 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Education: $32.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.16 |
| Education | $32.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $401.29 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $269.23 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $232.11 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $203.44 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $161.84 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $114.94 | 2022-2025 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $104.96 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $104.53 | 2019-2024 | Ultomiris |
| Bard Peripheral Vascular, INC. | $100.58 | 2025 | Covera |
| Horizon Therapeutics Plc | $94.84 | 2020-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $89.43 | 2019-2024 | Benlysta |
| Akebia Therapeutics INC | $84.68 | 2021-2023 | Auryxia |
| Ardelyx, INC. | $76.27 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $65.16 | 2019-2023 | Alunbrig |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.